Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Neurocrine Takes Strike 2 On VMAT2

Right up until today, Neurocrine (NASDAQ:NBIX) had been a pretty strong call for me. I last wrote about this biotech for Seeking Alpha on September 18 ("Neurocrine Still Looks Significantly Underrated"), and the stock had been up more than 100% since then. While making money in biotechs has hardly been difficult over the last year, a lot of optimism had been building around both Neurocrine's endometriosis and fibroid treatment Elagolix (being developed under license by AbbVie (NYSE:ABBV)) and its VMAT2 inhibitor ('854) for tardive dyskenesia (TD).

That all came to a screeching halt when Neurocrine announced yet another Phase II trial failure for '854 in TD. Although the KINECT-1 study may not be technically a failure,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details